svpn news
reuters.com ↗
A U.S. court on Monday allowed Eli Lilly to continue weight-loss drug advertisements that rival Novo Nordisk claimed were false and misleading.
Log in or sign up to comment.
No comments yet.
← Back to stories
or login to continue
Already have an account? Log in
Log in or sign up to comment.